The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer (Q34806737)

4 August 2017

6 references

25 June 2019

31 July 2019

28 September 2019

15 December 2019

13 November 2020

24 November 2020

The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer (English)

1 reference

4 August 2017

cell surface receptor

1 reference

31 July 2019

1 reference

28 September 2019

1 reference

15 December 2019

1 reference

1 reference

13 November 2020

1 reference

24 November 2020

Q Sheng

1

1 reference

4 August 2017

J Liu

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

British Journal of Cancer

4 August 2017

12 April 2011

6 references

25 June 2019

31 July 2019

28 September 2019

15 December 2019

13 November 2020

24 November 2020

7 references

4 August 2017

25 June 2019

31 July 2019

28 September 2019

15 December 2019

13 November 2020

24 November 2020

104

1 reference

4 August 2017

1241-1245

1 reference

4 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.62

4 August 2017

0 references

cites work

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

A growing family: adding mutated Erbb4 as a novel cancer target

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Epidermal growth factor receptor (EGFR) signaling in cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Global cancer statistics, 2002

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Neuregulin expression, function, and signaling in human ovarian cancer cells.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

c-erbB-3 protein expression in ovarian tumours

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Expression of the ErbB family of receptors in ovarian cancer.

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.62

ErbB-3 predicts survival in ovarian cancer.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.62

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078592

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364581

12 December 2020

inferred from PubMed ID database lookup

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364581

12 December 2020

inferred from PubMed ID database lookup

Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364581

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/BJC.2011.62

1 reference

Dimensions Publication ID

4 August 2017

1005292702

0 references

Fatcat ID

release_i7bwspji5nb63hb4pcjquajn4y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i7bwspji5nb63hb4pcjquajn4y

24 November 2022

mapped directly with Wikidata item

PMCID

3078592

1 reference

4 August 2017

1 reference